Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients.

Related Articles Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol. 2019 Mar 14;25(10):1266-1277 Authors: Foster AJ, Smyth M, Lakhani A, Jung B, Brant RF, Jacobson K Abstract BACKGROUND: Asymptomatic children with Crohn’s disease (CD) require ongoing monitoring to ensure early recognition of a disease exacerbation. AIM: In a cohort of pediatric CD patients, we aimed to assess the utility of serial fecal calprotectin measurements to detect intestinal inflammatory activity and predict disease relapse. METHODS: In this prospective longitudinal cohort study, children with CD…

Read More

Clinical Practice Guideline for the Management of Luminal Crohn’s Disease: The Toronto Consensus.

Related Articles Clinical Practice Guideline for the Management of Luminal Crohn’s Disease: The Toronto Consensus. Clin Gastroenterol Hepatol. 2019 Mar 07;: Authors: Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN Abstract BACKGROUND & AIMS: Crohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms…

Read More

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed. Aliment Pharmacol Ther. 2019 Mar;49(6):816-817 Authors: Gibson DJ, Ward MG PMID: 30811645 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30811645?dopt=Abstract

Read More

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy – early promise but more data needed. Authors’ reply.

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy – early promise but more data needed. Authors’ reply. Aliment Pharmacol Ther. 2019 Mar;49(6):817-818 Authors: Bouguen G, Siproudhis L PMID: 30811643 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30811643?dopt=Abstract

Read More

Streptococcus Salivarius: A Potential Salivary Biomarker for Orofacial Granulomatosis and Crohn’s Disease?

Streptococcus Salivarius: A Potential Salivary Biomarker for Orofacial Granulomatosis and Crohn’s Disease? Inflamm Bowel Dis. 2019 Feb 23;: Authors: Goel RM, Prosdocimi EM, Amar A, Omar Y, Escudier MP, Sanderson JD, Wade WG, Prescott NJ Abstract BACKGROUND: Orofacial granulomatosis (OFG) is a rare disease characterised by chronic, noncaseating, granulomatous inflammation primarily affecting the oral cavity. Histologically, it is similar to Crohn’s disease (CD), and a proportion of patients have both OFG and CD. The cause of OFG remains elusive, but it has been suggested that microbial interactions may be involved.…

Read More

Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries.

Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries. Inflamm Bowel Dis. 2019 Feb 22;: Authors: Hansen TM, Targownik LE, Karimuddin A, Leung Y Abstract Increasing uptake of biologic therapy has contributed to declining surgical rates for inflammatory bowel disease (IBD). However, a significant number of patients on biologic therapy will go on to require surgery. The literature is conflicted with regard to the preoperative management of biologic therapy before urgent or elective IBD surgery. This article reviews the available data on postoperative complications following preoperative treatment with anti-tumor…

Read More

Association Between Level of Fecal Calprotectin and Progression of Crohn’s Disease.

Association Between Level of Fecal Calprotectin and Progression of Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 Feb 14;: Authors: Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW Abstract BACKGROUND & AIMS: Mucosal healing is associated with improved outcomes in patients with Crohn’s disease (CD), but assessment typically requires ileocolonoscopy. Calprotectin can be measured in fecal samples to determine luminal disease activity in place of endoscopy-this measurement is an important component of the treat to target strategy. We investigated whether levels of fecal calprotectin associate with subsequent CD…

Read More

Long-term outcomes of Proactive therapeutic drug monitoring of adalimumab and standard of care in patients with inflammatory bowel disease.

Long-term outcomes of Proactive therapeutic drug monitoring of adalimumab and standard of care in patients with inflammatory bowel disease. J Crohns Colitis. 2019 Feb 07;: Authors: Dai C, Jiang M, Yu JH PMID: 30753387 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30753387?dopt=Abstract

Read More

Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease.

Related Articles Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Feb 07;: Authors: Chen P, Li Y, Li L, Yu Q, Chao K, Zhou G, Qiu Y, Feng R, Huang S, He Y, Chen B, Chen M, Zeng Z, Zhang S Abstract BACKGROUND: Owing to the importance of early treatment, simple and reliable methods for monitoring inflammatory bowel disease (IBD) are needed. AIMS: To determine whether circulating microRNAs are reliable biomarkers for IBD monitoring. METHODS: Serum levels of…

Read More

Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic de-escalation in patients with inflammatory bowel diseases.

Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic de-escalation in patients with inflammatory bowel diseases. J Crohns Colitis. 2019 Feb 06;: Authors: Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT Abstract Background and aims: To assess faecal calprotectin (Fcal) levels before and after therapeutic de-escalation to predict clinical relapse in patients with inflammatory bowel disease (IBD). Methods: From a prospectively-maintained database, we enrolled 160 IBD patients (112 Crohn’s disease/48…

Read More
<< Go Back